In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Early markers of right ventricular involvement in experimental chronic postcapillary pulmonary hypertension.

Session Poster Session 1

Speaker Ines Garcia Lunar

Event : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : Myocardial Disease
  • Session type : Poster Session

Authors : I Garcia Lunar (Madrid,ES), P Jorda (Barcelona,ES), D Pereda (Barcelona,ES), M Ascaso (Barcelona,ES), E Santiago (Madrid,ES), J Sanchez (Madrid,ES), C Galan (Madrid,ES), V Fuster (Madrid,ES), B Ibanez (Madrid,ES), A Garcia-Alvarez (Madrid,ES)

Authors:
I. Garcia Lunar1 , P. Jorda2 , D. Pereda2 , M. Ascaso2 , E. Santiago1 , J. Sanchez1 , C. Galan1 , V. Fuster1 , B. Ibanez1 , A. Garcia-Alvarez1 , 1Centro Nacional de Investigaciones Cardiovasculares, CNIC Carlos III - Madrid - Spain , 2Hospital Clinic de Barcelona - Barcelona - Spain ,

Topic(s):
Cardiac Magnetic Resonance: Myocardium

Citation:
European Heart Journal ( 2019 ) 40 ( Supplement ), 207

Background: In chronic pulmonary hypertension (PH), the main cause of death is right ventricular (RV) failure. However, the onset of RV dysfunction varies significantly among patients. Early recognition of RV maladaptation would be highly relevant.

Purpose: To identify cardiac magnetic resonance (CMR)-derived parameters affected in early stages of PH before the development of RV dysfunction.

Methods: Experimental chronic PH was generated by pulmonary vein banding in 76 pigs whereas 14 animals underwent sham operation. Animals were followed-up monthly with right heart catheterization (RHC) and immediate CMR for a maximum of 9 months. CMR exams included a T1-mapping sequence to quantify equilibrium-extracellular volume (ECV) at the RV insertion points. Pairs of RHC and CMR examinations were compared among controls and PH with normal RV ejection fraction (RVEF≥55%) or reduced (REVF<55%) using ANCOVA test with Bonferroni correction. All procedures followed the “Principles of laboratory animal care”.

Results: In the presence of PH confirmed by RHC and normal RVEF, the RV displays significant hypertrophy and increased myocardial native T1 and ECV, despite preserved ventricular dimensions and PA flow (Fig 1B). In advanced stages of the disease, RV-AP uncoupling and reduced PA pulsatility develop together with RV dilatation and failure (Fig 1C).

Conclusion: RV hypertrophy and ECV expansion are early mechanisms in RV adaptation to postcapillary PH, whereas ventricular and PA dilatation, RV-PA uncoupling and reduced pulsatility appear in more advanced stages concurring with systolic dysfunction.

CMR parameters in sham and PH animals
Sham controls (n=25 evaluations)PH with normal RVEF (n=155 evaluations)PH with low RVEF (n=70)
RVEF (%)62±561±447±8#
RVEDV (mL/m2)73±1883±17111±29#
RVESV (mL/m2)28±832±861±25#
RV mass (g/m2)17±423±5*30±11#
PA area (cm2/m2)5.5±1.26.3±1.68.7±2.2#
Native T1 anterior RVIP (ms)983±751043±78*1055±90#
ECV anterior RVIP (%)27±531±6*36±7#
Native T1 inferior RVIP (ms)959±681022±71*1032±99#
ECV inferior RVIP (%)25±531±6*36±7#
PA pulsatility (%)29±627±721±3#
Ea/Emax40±1647±1197±65#
RVEDV: RV end-diastolic volume; RVESV: RV end-systolic volume; RVIP: RV insertion point. *p<0.05 1 vs. 2; #1 vs. 3.
NativeT1: control, PH-normal RV, RV dysf

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are